Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus

Koen K.A. Van Rompay, Brian P. Kearney, Jonathan J. Sexton, Roxana Colón, Jonathan R. Lawson, Emily J. Blackwood, William A. Lee, Norbert Bischofberger, Marta Marthas

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Simian immunodeficiency virus (SIV) infection of infant macaques is a useful animal model of pediatric HIV infection to evaluate the potential of chemoprophylactic regimens to reduce mother-to-infant transmission of HIV. Previous studies have demonstrated that short-term subcutaneous administration of the reverse transcriptase inhibitor tenofovir was highly effective in protecting newborn macaques against infection after a single high-dose oral inoculation with virulent SIVmac251. In the current study, we mimicked HIV transmission through breast-feeding by repeatedly feeding infant macaques low doses of SIVmac251. Topical administration of a low dose of the second-generation tenofovir prodrug GS-7340 did not have detectable prophylactic efficacy. Oral administration of tenofovir disoproxil fumarate (DF; 10 mg/kg SID) lowered the infection rate at birth, but had lower efficacy against virus infection at 4 weeks of age, most likely because drug levels became suboptimal relative to those obtained with the current tenofovir DF regimen in humans. These prophylactic results further underscore the relevance of the current tenofovir DF prevention trials in pediatric and adult populations.

Original languageEnglish (US)
Pages (from-to)6-14
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume43
Issue number1
DOIs
StatePublished - Sep 1 2006

Fingerprint

Tenofovir
Simian Immunodeficiency Virus
Macaca
Virus Diseases
HIV
Pediatrics
Topical Administration
Reverse Transcriptase Inhibitors
Sudden Infant Death
Birth Rate
Prodrugs
Infection
Breast Feeding
HIV Infections
Oral Administration
Animal Models
Mothers
GS-7340

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. / Van Rompay, Koen K.A.; Kearney, Brian P.; Sexton, Jonathan J.; Colón, Roxana; Lawson, Jonathan R.; Blackwood, Emily J.; Lee, William A.; Bischofberger, Norbert; Marthas, Marta.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 43, No. 1, 01.09.2006, p. 6-14.

Research output: Contribution to journalArticle

Van Rompay, Koen K.A. ; Kearney, Brian P. ; Sexton, Jonathan J. ; Colón, Roxana ; Lawson, Jonathan R. ; Blackwood, Emily J. ; Lee, William A. ; Bischofberger, Norbert ; Marthas, Marta. / Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. In: Journal of Acquired Immune Deficiency Syndromes. 2006 ; Vol. 43, No. 1. pp. 6-14.
@article{b0df45029dc84375a7036074c7ea3cc8,
title = "Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus",
abstract = "Simian immunodeficiency virus (SIV) infection of infant macaques is a useful animal model of pediatric HIV infection to evaluate the potential of chemoprophylactic regimens to reduce mother-to-infant transmission of HIV. Previous studies have demonstrated that short-term subcutaneous administration of the reverse transcriptase inhibitor tenofovir was highly effective in protecting newborn macaques against infection after a single high-dose oral inoculation with virulent SIVmac251. In the current study, we mimicked HIV transmission through breast-feeding by repeatedly feeding infant macaques low doses of SIVmac251. Topical administration of a low dose of the second-generation tenofovir prodrug GS-7340 did not have detectable prophylactic efficacy. Oral administration of tenofovir disoproxil fumarate (DF; 10 mg/kg SID) lowered the infection rate at birth, but had lower efficacy against virus infection at 4 weeks of age, most likely because drug levels became suboptimal relative to those obtained with the current tenofovir DF regimen in humans. These prophylactic results further underscore the relevance of the current tenofovir DF prevention trials in pediatric and adult populations.",
author = "{Van Rompay}, {Koen K.A.} and Kearney, {Brian P.} and Sexton, {Jonathan J.} and Roxana Col{\'o}n and Lawson, {Jonathan R.} and Blackwood, {Emily J.} and Lee, {William A.} and Norbert Bischofberger and Marta Marthas",
year = "2006",
month = "9",
day = "1",
doi = "10.1097/01.qai.0000224972.60339.7c",
language = "English (US)",
volume = "43",
pages = "6--14",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus

AU - Van Rompay, Koen K.A.

AU - Kearney, Brian P.

AU - Sexton, Jonathan J.

AU - Colón, Roxana

AU - Lawson, Jonathan R.

AU - Blackwood, Emily J.

AU - Lee, William A.

AU - Bischofberger, Norbert

AU - Marthas, Marta

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Simian immunodeficiency virus (SIV) infection of infant macaques is a useful animal model of pediatric HIV infection to evaluate the potential of chemoprophylactic regimens to reduce mother-to-infant transmission of HIV. Previous studies have demonstrated that short-term subcutaneous administration of the reverse transcriptase inhibitor tenofovir was highly effective in protecting newborn macaques against infection after a single high-dose oral inoculation with virulent SIVmac251. In the current study, we mimicked HIV transmission through breast-feeding by repeatedly feeding infant macaques low doses of SIVmac251. Topical administration of a low dose of the second-generation tenofovir prodrug GS-7340 did not have detectable prophylactic efficacy. Oral administration of tenofovir disoproxil fumarate (DF; 10 mg/kg SID) lowered the infection rate at birth, but had lower efficacy against virus infection at 4 weeks of age, most likely because drug levels became suboptimal relative to those obtained with the current tenofovir DF regimen in humans. These prophylactic results further underscore the relevance of the current tenofovir DF prevention trials in pediatric and adult populations.

AB - Simian immunodeficiency virus (SIV) infection of infant macaques is a useful animal model of pediatric HIV infection to evaluate the potential of chemoprophylactic regimens to reduce mother-to-infant transmission of HIV. Previous studies have demonstrated that short-term subcutaneous administration of the reverse transcriptase inhibitor tenofovir was highly effective in protecting newborn macaques against infection after a single high-dose oral inoculation with virulent SIVmac251. In the current study, we mimicked HIV transmission through breast-feeding by repeatedly feeding infant macaques low doses of SIVmac251. Topical administration of a low dose of the second-generation tenofovir prodrug GS-7340 did not have detectable prophylactic efficacy. Oral administration of tenofovir disoproxil fumarate (DF; 10 mg/kg SID) lowered the infection rate at birth, but had lower efficacy against virus infection at 4 weeks of age, most likely because drug levels became suboptimal relative to those obtained with the current tenofovir DF regimen in humans. These prophylactic results further underscore the relevance of the current tenofovir DF prevention trials in pediatric and adult populations.

UR - http://www.scopus.com/inward/record.url?scp=33748097643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748097643&partnerID=8YFLogxK

U2 - 10.1097/01.qai.0000224972.60339.7c

DO - 10.1097/01.qai.0000224972.60339.7c

M3 - Article

C2 - 16810108

AN - SCOPUS:33748097643

VL - 43

SP - 6

EP - 14

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 1

ER -